PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.21%
Positive EBIT growth while GNPX is negative. John Neff might see a substantial edge in operational management.
40.44%
Positive operating income growth while GNPX is negative. John Neff might view this as a competitive edge in operations.
42.50%
Positive net income growth while GNPX is negative. John Neff might see a big relative performance advantage.
40.54%
EPS growth above 1.5x GNPX's 12.20%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
40.54%
Diluted EPS growth above 1.5x GNPX's 12.20%. David Dodd would see if there's a robust moat protecting these shareholder gains.
0.40%
Share reduction more than 1.5x GNPX's 210.32%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.40%
Diluted share reduction more than 1.5x GNPX's 210.32%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
51.97%
Positive OCF growth while GNPX is negative. John Neff would see this as a clear operational advantage vs. the competitor.
51.97%
Positive FCF growth while GNPX is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while GNPX stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
95.95%
10Y OCF/share CAGR in line with GNPX's 93.22%. Walter Schloss would see both as similarly efficient over the decade.
79.78%
5Y OCF/share CAGR at 75-90% of GNPX's 91.06%. Bill Ackman would push for operational improvements to match competitor’s mid-term gains.
21.40%
3Y OCF/share CAGR under 50% of GNPX's 86.77%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
95.64%
Similar net income/share CAGR to GNPX's 93.55%. Walter Schloss would see parallel tailwinds or expansions for both firms.
74.54%
5Y net income/share CAGR at 75-90% of GNPX's 92.90%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
42.66%
Below 50% of GNPX's 91.61%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
160.55%
Positive growth while GNPX is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
2.24%
Positive 5Y equity/share CAGR while GNPX is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-69.25%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 5Y dividend/share CAGR while GNPX stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.35%
Negative asset growth while GNPX invests at 5.56%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-14.61%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-8.07%
We’re deleveraging while GNPX stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-50.78%
Our R&D shrinks while GNPX invests at 2.99%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-4.70%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.